Cargando…

Beyond the Checkpoint: Severe Axitinib-induced Liver Injury

Understanding the potential adverse effects associated with oncological treatments is crucial in the clinical care of patients with cancer. We describe the first case report delineating severe acute liver injury secondary to axitinib. This is a case of metastatic renal cell carcinoma treated with ax...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Yee Hui, Ayoub, Walid, Yang, Ju Dong, Kuo, Alexander, Trivedi, Hirsh D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627582/ https://www.ncbi.nlm.nih.gov/pubmed/37937065 http://dx.doi.org/10.14309/crj.0000000000001177

Ejemplares similares

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
por: Yeo, Yee Hui, et al.
Publicado: (2023)

A Case Report with Severe Thrombocytopenia Induced by Axitinib
por: Koksal, Ulkuhan I., et al.
Publicado: (2020)

Traditional Chinese Medicine, Cordyceps, Related to Hepatoportal Sclerosis
por: Kaur, Bhupinder, et al.
Publicado: (2023)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
por: Kerr, Lauren T., et al.
Publicado: (2016)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
por: Grünwald, Viktor, et al.
Publicado: (2020)

Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
por: Kadowaki, Hiroshi, et al.
Publicado: (2021)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
por: Hillman, Gilda G., et al.
Publicado: (2014)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
por: Roberts, Jane L., et al.
Publicado: (2021)

Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond
por: Tinawi, Mohammad, et al.
Publicado: (2020)

Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner
por: Morelli, Maria Beatrice, et al.
Publicado: (2016)

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
por: Shah, Manan, et al.
Publicado: (2020)

Drug‐Induced Liver Injury by Checkpoint Inhibitors: Benefit of a Causality Assessment Tool
por: Weber, Sabine, et al.
Publicado: (2020)

Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis
por: Qin, Fei, et al.
Publicado: (2018)

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer
por: Deshpande, Hari A, et al.
Publicado: (2010)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
por: Fu, Ying, et al.
Publicado: (2022)

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
por: Dicitore, Alessandra, et al.
Publicado: (2023)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
por: Heine, Annkristin, et al.
Publicado: (2015)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_45m7qrn74fv539uip50mec09ok